SCHEMBL4840274

SCHEMBL4840274

COC(=O)CC(=O)c1c(C(=O)OC)n(C)c2cc(F)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 4/20 0.40
MAPK9 P45984 4/20 0.40
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40
TUBB2A Q13885 1/20 0.40
TUBB8 Q3ZCM7 1/20 0.40
TUBA3E Q6PEY2 1/20 0.40
TUBA1A Q71U36 1/20 0.40
TUBA1C Q9BQE3 1/20 0.40
TUBB6 Q9BUF5 1/20 0.40
TUBB2B Q9BVA1 1/20 0.40
TUBB1 Q9H4B7 1/20 0.40
MAPT P10636 4/20 0.39
HPGD P15428 4/20 0.39
TSHR P16473 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5747438 0.90 MAPK8 (0.42) MAPK8MAPK9TUBB4ATUBBTUBA3C
SCHEMBL4843076 0.87 MAPK8 (0.39) MAPK8MAPK9TUBB4ATUBBTUBA3C
SCHEMBL5786235 0.82 PABPC1 (0.40) MAPK8MAPK9TUBB4ATUBBTUBA3C
SCHEMBL3933284 0.80 TSHR (0.42) MAPK8MAPK9MAPTHPGDTSHR
SCHEMBL29834837 0.79 MAPK8 (0.40) MAPK8MAPK9TUBB4ATUBBTUBA3C
SCHEMBL27605378 0.77 MAPK14 (0.39) MAPK8MAPK9TUBB4ATUBBTUBA3C
SCHEMBL4841109 0.76 ALOX15 (0.50) MAPK8MAPK9HPGDTSHRALDH1A1
SCHEMBL17959424 0.76 ALOX15 (0.47) HPGDTSHRALDH1A1HSD17B10LMNA
SCHEMBL5235896 0.76 KMT2A (0.48) MAPTHPGDTSHRATMALDH1A1
SCHEMBL5746650 0.75 MAPK8 (0.45) MAPK8MAPK9TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100543016-C Intermediate compounds of 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino [4, 5-b ] indole-1-acetamide derivatives SANOFI AVENTIS (FR) 2009-09-23 CN disclosed
US-20080255129-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-10-16 US disclosed
CN-100406459-C 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino [4, 5-b ] indole-1-acetamide derivatives, their preparation and use in therapy SANOFI AVENTIS (FR) 2008-07-30 CN disclosed
US-7405306-B2 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-07-29 US disclosed
US-20080076775-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-03-27 US disclosed
US-7323467-B2 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-01-29 US disclosed
US-20070219202-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5 b]indole-1-acetamide derivatives, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2007-09-20 US disclosed
US-7235554-B2 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments SANOFI-AVENTIS (FR) 2007-06-26 US disclosed
CN-1970538-A Intermediate compounds of 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino [4, 5-b ] indole-1-acetamide derivatives SANOFI AVENTIS (FR) 2007-05-30 CN disclosed
CN-1656099-A 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino [4, 5-b ] indole-1-acetamide derivatives, their preparation and use in therapy SANOFI AVENTIS (FR) 2005-08-17 CN disclosed
US-20050124615-A1 3-heteroarly-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments SANOFI (FR) 2005-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076775-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics IDO1, IDO2, TPH1 MAPK8 2034/4885MAPK9 4359/4885TUBB4A 1239/4885
US-20050124615-A1 3-heteroarly-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments HRH4, IDO1, HTR4 MAPK8 4380/4885MAPK9 4772/4885TUBB4A 721/4885
US-20070219202-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5 b]indole-1-acetamide derivatives, their preparation and their application in therapeutics IDO1, IDO2, TPH1 MAPK8 2304/4885MAPK9 4137/4885TUBB4A 1171/4885
US-20080255129-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics IDO1, IDO2, TPH1 MAPK8 2034/4885MAPK9 4359/4885TUBB4A 1239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.